Vivo Capital LLC Has $12.92 Million Stock Holdings in Geron Corporation $GERN

Vivo Capital LLC trimmed its position in shares of Geron Corporation (NASDAQ:GERN) by 68.1% during the first quarter, HoldingsChannel reports. The firm owned 8,671,797 shares of the biopharmaceutical company’s stock after selling 18,553,495 shares during the quarter. Geron comprises 1.1% of Vivo Capital LLC’s portfolio, making the stock its 27th largest holding. Vivo Capital LLC’s holdings in Geron were worth $12,921,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in GERN. 55 North Private Wealth LLC bought a new stake in shares of Geron in the 4th quarter valued at $29,000. LCM Capital Management Inc lifted its holdings in Geron by 80.6% during the fourth quarter. LCM Capital Management Inc now owns 22,400 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 10,000 shares in the last quarter. Vistica Wealth Advisors LLC acquired a new position in Geron in the fourth quarter valued at about $33,000. Caitong International Asset Management Co. Ltd grew its stake in Geron by 3,307.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 25,148 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 24,410 shares during the period. Finally, Hsbc Holdings PLC acquired a new position in Geron in the first quarter valued at about $33,000. Institutional investors and hedge funds own 73.71% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered Geron from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 24th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Geron currently has an average rating of “Hold” and an average price target of $4.00.

Geron Stock Performance

Shares of GERN opened at $1.35 on Friday. The firm has a market cap of $863.49 million, a P/E ratio of -12.24 and a beta of 0.60. Geron Corporation has a twelve month low of $1.04 and a twelve month high of $2.01. The company has a debt-to-equity ratio of 0.52, a quick ratio of 4.96 and a current ratio of 6.78. The firm’s 50 day moving average price is $1.32 and its two-hundred day moving average price is $1.46.

Geron (NASDAQ:GERN) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.02. Geron had a negative net margin of 35.48% and a negative return on equity of 23.31%. The company had revenue of $51.84 million during the quarter, compared to the consensus estimate of $50.59 million. On average, analysts forecast that Geron Corporation will post -0.02 EPS for the current fiscal year.

Geron Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.